Bristol-Myers, Sanofi ordered to pay Hawaii $834 million over Plavix warning label By Reuters

© Reuters. FILE PHOTO: Bottles of Plavix shown on display at a pharmacy in North Aurora, Illinois.

(Reuters) – Bristol-Myers Squibb (NYSE:) Co and Sanofi (NASDAQ:) SA were ordered by a U.S. judge on Monday to pay more than $834 million to the state of Hawaii for failing to properly warn non-white patients of health risks from its blood thinner Plavix.

The companies had failed to change the drug’s label to warn doctors and patients despite knowing some of the risks for more than a decade, U.S. District Judge Dean Ochiai in Honolulu wrote in the ruling.

Bristol-Myers and Sanofi, which produce Plavix in a partnership, said in a joint statement the decision was not supported by the overwhelming body of scientific evidence and vowed to appeal.

“The penalties awarded by the court are wholly unsupported, particularly given that the State of Hawaii provided no evidence that even a single person has been harmed by Plavix,” the companies said.

Ochiai, who issued the ruling following a four-week trial conducted entirely over Zoom without a jury, awarded $1,000 in damages for every Plavix prescription filled in Hawaii between 1998 and 2010.

Hawaii alleged that the companies violated state consumer protection laws by marketing Plavix without disclosing that the drug could have a diminished or no effect for some people, particularly of East Asian and Pacific Island ancestry.

Plavix is prescribed to prevent strokes and heart attacks. The blood thinner needs to get activated by the body’s own enzymes, which can vary genetically. Studies have shown that about 14% of Chinese patients are unable to properly metabolize the drug, compared to 4% of black and 2% of white patients.

The U.S. Food and Drug Administration in 2010 issued a new Plavix warning label to reflect that information.

Bristol-Myers and Sanofi still face a similar lawsuit over Plavix by the state of New Mexico.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button